Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

(2012) Ralf-Dieter Hofheinz et al.   LANCET ONCOLOGY

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

(2011) C. Twelves et al.   ANNALS OF ONCOLOGY

Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial

(2011) R. X. Zhang et al.   ANNALS OF ONCOLOGY

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

(2011) S Stintzing et al.   BRITISH JOURNAL OF CANCER

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

(2011) J Cassidy et al.   BRITISH JOURNAL OF CANCER

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group

(2011) Nicolas Moosmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast Cancer

(2010) Tetsuya Taguchi et al.   CHEMOTHERAPY

Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

(2010) Sherry L. Wolf et al.   JOURNAL OF CLINICAL ONCOLOGY

Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study

(2010) Yoon-Koo Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

(2008) M. L. Rothenberg et al.   ANNALS OF ONCOLOGY

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY